Merck Spins Out Biosimilars And Legacy Brands
New Company To Include Women’s Health, Legacy Brands And Biosimilars
Merck has announced plans to spin off its Biosimilars, Women’s Health and Legacy Brands units into a separate company.
You may also be interested in...
While in possession of a token biosimilar portfolio and pipeline, Sanofi has made it clear that its R&D dollars are unlikely to be spent on biosimilars, six months after reshaping its pipeline by exiting diabetes and cardiovascular diseases research.
Merck & Co has launched Ontruzant, the trastuzumab biosimilar developed and manufactured by Samsung Bioepis, in the US following a staggered approval process and earlier intellectual-property hurdles. The list price discount offered by the firm puts it in the middle of the pack among the four other biosimilar players currently on the market.
Although Merck has not yet debuted the Ontruzant version of trastuzumab developed by Samsung Bioepis in the US, the firm can now look to introduce two strengths of the Herceptin biosimilar, ahead of plans to spin off its biosimilar assets into a new company next year.